The company’s board reiterated its recommendation to instead pursue an offer from SK Capital and Carlyle that’s worth about ...

This year’s Breakthrough Prize—popularly known as the “Oscars of Science”—brought the world’s leading scientists together ...

Sickle cell experts say the future of a critical data collection program is in flux after staff at the CDC's Division of ...

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

Thalassemia and Sickle Cell Anaemia are common genetic disorders, with options for treatment and prevention available.

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

David Liu, Joel Habener, and Alberto Ascherio are among recipients of this year's six Breakthrough Prizes, the "Oscars of ...

The first patient is scheduled to begin therapy at Yas Clinic Hospital in April. The Department of Health – Abu Dhabi (DoH) has announced the launch of CASGEVY, a CRISPR/Cas9 gene-editing therapy ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.

a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., ...